78686-79-0

Basic information

• Product Name: Methyl 5-bromo-2-chloropyridine-3-carboxylate
• Synonyms: METHYL 5-BROMO-2-CHLORONICOTINATE;METHYL 5-BROMO-2-CHLOROPYRIDINE-3-CARBOXYLATE;Methyl 5-bromo-2-chloronicotinate 98%;methyl 5-bromo-2-chloro-3-pyridinecarboxylate;5-BROMO-2-CHLORONICOTINIC ACID METHYL ESTER;Methyl 5-bromo-2-chloropyridine-3-carboxylate, 5-Bromo-2-chloro-3-(methoxycarbonyl)pyridine;Methyl 5-broMo-2-chloronicotinate, 95+%;5-Bromo-2-chloropyridine-3-carboxylic acid methyl ester
• CAS NO: 78686-79-0
• Molecular Formula: C₇H₅BrClNO₂
• Molecular Weight: 250.48
• Product Categories: blocks;Bromides;Carboxes;Pyridines;Pyridine;Esters
• Mol File: 78686-79-0.mol

Chemical Properties

• Melting Point: 50-52°C
• Boiling Point: 275.6 °C at 760 mmHg
• Flash Point: >110 °C
• Appearance: /Solid
• Density: 1.684 g/cm³
• Vapor Pressure: 0.00504mmHg at 25°C
• Refractive Index: 1.568
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: soluble in Methanol
• PKA: -3.78±0.10(Predicted)
• Sensitive: Light, Air & Moisture Sensitive
• CAS DataBase Reference: Methyl 5-bromo-2-chloropyridine-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5-bromo-2-chloropyridine-3-carboxylate(78686-79-0)
• EPA Substance Registry System: Methyl 5-bromo-2-chloropyridine-3-carboxylate(78686-79-0)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 78686-79-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Methyl 5-bromo-2-chloropyridine-3-carboxylate is used as a building block in organic synthesis for its ability to participate in various chemical reactions. Its unique structure allows for the creation of a wide range of new chemical compounds, contributing to the development of novel materials and products.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Methyl 5-bromo-2-chloropyridine-3-carboxylate is used as a key intermediate in the synthesis of various drug candidates. Its versatility in chemical reactions enables the development of new pharmaceutical compounds with potential therapeutic applications.
Used in Medicinal Chemistry:
Methyl 5-bromo-2-chloropyridine-3-carboxylate is employed in medicinal chemistry as a valuable component for the design and synthesis of bioactive molecules. Its unique structural features and reactivity make it a promising candidate for the development of new drugs with improved efficacy and selectivity.
Used in Chemical Research:
In the field of chemical research, Methyl 5-bromo-2-chloropyridine-3-carboxylate is utilized as a model compound to study various chemical reactions and mechanisms. Its reactivity and structural properties provide valuable insights into the behavior of similar compounds and contribute to the advancement of chemical knowledge.
Overall, Methyl 5-bromo-2-chloropyridine-3-carboxylate is a versatile and important chemical compound with a wide range of applications in various industries, including organic synthesis, pharmaceutical research, medicinal chemistry, and chemical research. Its unique properties and reactivity make it a valuable building block for the development of new chemical and pharmaceutical compounds.

InChI:InChI=1/C7H5BrClNO2/c1-12-7(11)5-2-4(8)3-10-6(5)9/h2-3H,1H3

Upstream product

• 186581-53-3 diazomethane 
• 29241-65-4 5-bromo-2-chloronicotinic acid 
• 609-71-2 2-hydroxy-3-carboxypyridine 
• 67-56-1 methanol 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 104612-36-4 5-bromo-2-hydroxynicotinic acid 
• 609-71-2 1,2-dihydro-2-oxonicotinic acid 
• 10128-91-3 methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile 
• 120034-05-1 5-bromo-2-oxo-1,2-dihydropyridine-3-carboxylic acid methyl ester 
• 78686-86-9 5-bromo-2-chloro-pyridine-3-carbonyl chloride 

Downstream Products

• 120034-09-5 1,4-bis<4-(tert-butoxycarbonyl)phenyl>-1,3-butadiyne 
• 1017782-99-8 methyl 5-bromo-2-morpholinonicotinate 
• 1384262-76-3 3-Bromo-6-(4-methoxybenzyl)-7,8-dihydro-1,6-naphthyridin-5(6H)-one 

Relevant articles and documents

Nitrogen-containing heterocyclic compound as well as preparation method, pharmaceutical composition and application thereof

The invention provides a nitrogen-containing heterocyclic compound as well as a preparation method, a pharmaceutical composition and application thereof, and particularly provides a compound as shownin a formula I which is described in the specification,

SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE

The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R2, R3, R10, E1, E2, E3, Y, and Z are as defined herein.

NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Design, Synthesis, and Evaluation of Novel Auxin Mimic Herbicides

Due to the key roles of auxins as master regulators of plant growth, there is considerable interest in the development of compounds with auxin-like properties for growth management and weed control applications. Herein, we describe the design and multiste

PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS

There are provided inter alia pyrazolyl-substituted pyridone compounds, which exhibit biological activity, e.g., inhibitory action, against serine proteases, including thrombin and various kallikreins. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which disease or disorder is amenable to treatment or prevention by the inhibition of serine proteases, including thrombin and various kallikreins.

COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE

A method of inhibiting drug -resistant HIV-1 integrase in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, having a struc

NAPHTHYRIDINONE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS

In one aspect, the invention relates to naphthyridinone analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

DIHYDRONAPHTHYRIDINYL(ORGANO)METHANONE ANALOGS AS POSITIVE ALLOSTERIC MGLUR5 MODULATORS

In one aspect, the invention relates to dihydronaphthyridinyl(organo)methanone analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS

The invention relates to chemical compounds of formula (IB): or a salt thereof. In some embodiments, the invention relates to inhibitors of UDP-3-0 — (R-S-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC). In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein and their use in the prevention and/or treatment of Gram- negative bacterial infections.

MET kinase inhibitors

The present invention is directed to compounds having the formula I or II: including salts thereof, and methods for using them for the treatment of cancer.